Trial | NCT04183387  Report issue

Title

Simvastatin in Uveitis
Open-label Randomized Study of Efficacy and Safety of Simvastatin in Uveitis

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    50
The study evaluates anti-inflammatory effects and safety of simvastatin in non-infectious uveitis.
3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors (statins) have been shown to reduce local and systemic inflammation in animal models of various autoimmune disorders including uveitis. In this open-label, randomized study clinical efficacy and tolerability of simvastatin 40 mg/day for 8 weeks is evaluated.
Study Started
Sep 30
2014
Primary Completion
Jan 31
2016
Study Completion
Jan 31
2016
Last Update
Dec 03
2019

Drug Simvastatin 40mg

  • Other names: simvastatin

Simvastatin and standard treatment Experimental

40 mg simvastatin per day for 2 months in addition to conventional treatment of uveitis

standard treatment No Intervention

conventional treatment of uveitis

Criteria 

Inclusion Criteria:

- diagnosis of active non-infectious uveitis

Exclusion Criteria:

serious liver or kidney disease
increased transaminase levels of >1.5 ULN
planned or active pregnancy
use of fibrates, nicotinic acid, cyclosporine A, antifungal drugs, macrolide antibiotics, verapamil, and grapefruit juice (>1 L/day).
No Results Posted